Actively Recruiting
Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology
Led by Qilu Hospital of Shandong University · Updated on 2026-01-30
254
Participants Needed
1
Research Sites
312 weeks
Total Duration
On this page
Sponsors
Q
Qilu Hospital of Shandong University
Lead Sponsor
T
The Second Hospital of Shandong University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study, through a clinical controlled trial, compared the one-year, three-year, and five-year overall survival rates between patients receiving a treatment plan guided by organoid drug sensitivity and those receiving conventional empirical treatment. Univariate Kaplan-Meier survival analysis was used to compare the differences in overall survival between the two groups. The study aimed to evaluate the application value of tumor organoid drug sensitivity testing in guiding neoadjuvant chemotherapy for bladder cancer.
CONDITIONS
Official Title
Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years, any gender
- Diagnosed with clinical stage T2 to T4a muscle-invasive bladder cancer without distant metastasis
- Have not previously received systemic chemotherapy
- Able to tolerate platinum-based combination neoadjuvant chemotherapy
- ECOG performance status between 0 and 2
- Able to follow the trial protocol, cooperate with monitoring and follow-up
- Voluntarily agree to participate and have signed informed consent
You will not qualify if you...
- Muscle-invasive bladder cancer patients with clinical stage T4b or distant metastasis
- Unable to tolerate radical cystectomy
- Have immunodeficiency or are on immunosuppressants or radiotherapy
- Known allergies to study drugs or components
- Long-term use of hormonal drugs or history of drug abuse
- Pregnant, breastfeeding, or planning pregnancy
- Abnormal blood counts or liver, kidney, coagulation dysfunctions beyond specified limits
- Diagnosis of myelodysplastic syndrome or acute myeloid leukemia
- History of neurological or psychiatric disorders affecting safety
- Serious concomitant diseases that risk patient safety or study completion
- Other factors deemed by the investigator to contraindicate participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qilu Hospital of Shandong University
Jinan, China
Actively Recruiting
Research Team
J
Jun Chen
CONTACT
J
Jingchao Liu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here